RT @JackWestMD : My top 5 practice-changing highlights in LC for 20171) PACIFIC trial: durvalumab in st 3 NSCLC2) FDA approval of KN-21g3…

RT @JackWestMD : My top 5 practice-changing highlights in LC for 2017 1) PACIFIC trial: durvalumab in st 3 NSCLC 2) FDA approval of KN-21g 3…

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://twitter.com/ecancer/status/948109070761910272
via IFTTT